<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932071</url>
  </required_header>
  <id_info>
    <org_study_id>ChiCTR-IPR-16008568</org_study_id>
    <nct_id>NCT03932071</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma</brief_title>
  <official_title>The Efficacy of New Adjuvant Chemotherapy of Osteosarcoma Combined With Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been
      widely used in the treatment of metastatic bone tumors. In addition to its inhibition of
      tumor osteoclasis, it also produces certain killing of tumor cells. effect. Foreign studies
      have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain
      inhibitory effect on distant metastasis. We hope that it can reduce tumor recurrence and lung
      metastasis through this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of lung metastasis</measure>
    <time_frame>3 year</time_frame>
    <description>Discovery the rate of neonatal lung metastases by high-resolution chest CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of tumor recurrence</measure>
    <time_frame>3 year</time_frame>
    <description>Local recurrence rate of tumor or rate of distant metastasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of tumor necrosis less than 90%</measure>
    <time_frame>3 year</time_frame>
    <description>the rate of patients that postoperative tumor necrosis rate was estimated to be lower than grade III（90%）</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lung Metastases</condition>
  <condition>Tumor Necrosis</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with osteosarcoma who were diagnosed with initial pathology and pathology
             were excluded from lung metastasis or other metastatic lesions by CT and total body
             emission-computed tomography, and patients with standard chemotherapy were evaluated.

        Exclusion Criteria:

          -  Pulmonary metastasis, pregnancy or lactation, renal insufficiency (creatinine
             clearance &lt;70 ml/min/1.73 m2), liver dysfunction, obvious oral disease, and unsuitable
             for bisphosphonate treatment after evaluation, have been found. With diseases that
             still require hormone therapy, abnormal blood system, heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhaoming Ye, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Affiliated Hospital Of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaobo Yan, Dr.</last_name>
    <phone>+8613588153306</phone>
    <email>yanxiaobo82@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaobo Yan</last_name>
      <phone>13588153306</phone>
      <email>yanxiaobo82@gmail.com</email>
    </contact>
    <investigator>
      <last_name>zhaoming Ye, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</investigator_affiliation>
    <investigator_full_name>Zhaoming Ye</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

